Velo-cardio-facial syndrome (VCFS) and DiGeorge syndrome (DGS) are developmental disorders characterized by a spectrum of phenotypes including velopharyngeal insufficiency, conotruncal heart defects and facial dysmorphology among others. Eighty to eighty-five percent of VCFS/DGS patients are hemizygous for a portion of chromosome 22. It is likely that the genes encoded by this region play a role in the etiology of the phenotypes associated with the disorders. Using a cDNA selection protocol, we isolated a novel clathrin heavy chain cDNA (CLTD) from the VCFS/DGS minimally deleted interval. The cDNA encodes a protein of 1638 amino acids. CLTD shares significant homology, but is not identical to the ubiquitously expressed clathrin heavy chain gene. The CLTD gene also shows a unique pattern of expression, having its maximal level of expression in skeletal muscle. Velopharyngeal insufficiency and muscle weakness are common features of VCFS patients. Based on the location and expression pattern of CLTD, we suggest hemizygosity at this locus may play a role in the etiology of one of the VCFS-associated phenotypes.
INTRODUCTION
Velo-cardio facial syndrome (VCFS MIM19243), originally described by Shprintzen in 1978 (1) , has an estimated incidence of 1 in 5000 (2) . A majority of VCFS cases are sporadic, and familial cases show an autosomal dominant pattern of inheritance (3) . Characteristic features of this syndrome include conotruncal cardiac abnormalities, velopharyngeal insufficiency (VPI), clefting of the soft palate (vellum), hypernasal speech, learning disabilities and mild facial dysmorphology (1, (4) (5) (6) (7) (8) (9) . To date, >40 phenotypes have been described in association with VCFS, including psychiatric disorders, microcephaly, hypotonia and renal agenesis (1, (10) (11) (12) (13) (14) . The phenotypic spectrum of VCFS overlaps with that of DiGeorge syndrome (DGS) (15, 16) , which is generally considered to be a more severe disorder encompassing many of the VCFS phenotypes with the additional features of thymic gland aplasia and hypoparathyroidism (16, 17) . Both syndromes may share a common etiology.
VCFS and DGS have been associated with haploinsufficiency of a portion of chromosome 22q11. Cytogenetically detectable deletions of 22q11 were the first evidence of linkage of these disorders to chromosome 22 (18) (19) (20) (21) . Dosage analysis (22) (23) (24) (25) , fluorescence in situ hybridization (FISH) (26, 27) and, more recently, polymorphic marker analysis (28) confirmed that 80-85% of patients have detectable deletions. A minimal region of overlap that is deleted in VCFS patients, termed the critical region, was estimated to be 1-2 Mb in length (27) . The remaining set of patients may carry a small deletion or a point mutation in a critical gene or may be phenocopies with a different etiology.
Several of the organs and tissues affected in VCFS patients are of neural crest origin and are derived from the third and fourth pharyngeal pouches. Therefore, VCFS has been considered to be a developmental field defect and may result from haploinsufficiency of one or more genes from the interval that is commonly deleted in patients. Although the cardinal features of VCFS might result from the haploinsufficiency of a single gene, additional features associated with VCFS might result from haploinsufficiency of other genes located in the deleted interval in each patient. Therefore, to fully understand the molecular basis of the VCFS-associated phenotypes, it is necessary to isolate all the genes encoded in the 22q11 region and ascertain their role in each of the phenotypes associated with VCFS. Towards this goal, we constructed a physical map of 22q11 and defined a region that is commonly deleted in VCFS patients (28) . We have also begun a systematic effort to isolate the genes in this interval. Here we describe the isolation and characterization of a new gene which shows considerable homology to the clathrin heavy chain gene (CLTC) which has been mapped to chromosome 17 (29) . The new gene, designated clathrin D (CLTD) is located in the VCFS commonly deleted interval. Although clathrin is ubiquitous and plays a critical role in both endocytosis and exocytosis (30) , CLTD is most abundantly expressed in adult skeletal muscle. Skeletal muscle insufficiency and weakness are associated with VCFS. VPI is present in >90% of VCFS patients and results from hypoplasia and hypotonia of the lateral pharyngeal wall musculature. A more generalized hypotonia during infancy was also among the initial phenotypes described in VCFS (1) . We propose that hemizygosity of CLTD may play a role in the hypotonia that is a common feature of VCFS patients.
RESULTS

Isolation of a novel clathrin heavy chain isoform
To isolate genes from the VCFS critical region, the 250 kb ICRF (Imperial Cancer Research Fund) YAC, Y5A11 (28, 31) , was used as a substrate for cDNA selection (32) (33) (34) . Total DNA from the yeast clone was digested with HindIII, immobilized onto nylon membranes and hybridized with a composite of human short fragment cDNA libraries prepared by pooling six individual cDNA libraries from total fetus (8-9 week abortus), fetal brain, adult brain, spleen, testes and thymus. The initial insert size of the libraries was in the range of 300-2000 bp. The cDNAs that hybridized to the membrane were PCR amplified and used for a second round of hybridization selection. Amplified material from the second round of hybridization selection containing cDNAs putatively arising from genes on the YAC Y5A11 were cloned into the λgt10 vector for analysis. The plaques were screened with rDNA probes and 25 non-hybridizing inserts were sequenced. The sequences were examined for homologies among sequences deposited in the GenBank/EMBL databases using the BlastN and BlastX algorithms.
One of these phage inserts, termed V1-5, was 301 bp in length and showed a strong similarity to the human, rat and Drosophila clathrin heavy chain (CHC) genes at both the nucleotide and deduced amino acid levels. Of particular interest was the observation of substantial differences at the nucleotide level from the previously described human gene, CLTC (GenBank accession no. 434761), suggesting that we discovered a gene that corresponds to a novel CHC isoform.
Mapping of the new clathrin heavy chain gene to 22q11
The human clathrin heavy chain gene (CLTC) had previously been mapped to chromosome 17q11-qter (29) . The V1-5 cDNA fragment was obtained by using a YAC which contained chromosome 22 markers, suggesting that the gene corresponding to V1-5 is located on chromosome 22. To ascertain the validity of this assignment, genomic DNA from a panel of somatic cell hybrids (35) was screened with PCR primers designed from the V1-5 cDNA sequence (RK1138/RK1139). This panel permits unambiguous distinction between genes on chromosomes 17 and 22. The primer pair yielded the expected 119 bp amplification product from total human genomic DNA, DNA from a somatic cell hybrid containing only chromosome 22, GM10888 and from XOL-2, a hybrid that contains both chromosome 17 and 22 ( Fig.  1) . A PCR product was not produced from DNA from somatic cell hybrids, DUA-3BSAGA, WIL-14, WIL-15, WIL-2, WIL-6 (35) that contain chromosome 17 but not chromosome 22 or in hybrid 35R14 which contains neither human chromosome 17 or 22. Conversely, primers designed from the CLTC sequence (RK1187/RK1188) yielded a 290 bp amplification product on human genomic DNA and genomic DNA from cell lines containing chromosome 17 (data not shown). These results confirmed the notion that there are two human clathrin heavy chain loci, one on chromosome 17 and the second located on chromosome 22. We designate the second locus, located on chromosome 22, clathrin D, (CLTD).
To place the CLTD gene on the physical map of chromosome 22 (28, 31) , DNA from the CEPH mega YACs 706B10 and R14FC6, which are known to overlap with Y5A11 and contain chromosome 22 markers, were used for Southern blot analysis. DNA from Y5A11, 706b10 and R14FC6 was digested with EcoRI, blotted and hybridized with a CLTD probe (Fig. 2) . The probe detected a 5 kb band in human DNA and in three of the YACs from 22q11, including the Y5A11 YAC used for the cDNA selection. The V1-5 EST also produced an amplification product from the Y5A11, 706b10 and R14FC6 YACs as well as YACs 659h5 and R16IH4 (data not shown). These results confirmed the genomic localization of the CLTD locus to 22q11 and positioned the locus between markers D22S946/D22S947 and D22S945 (28, 31) .
Isolation of large insert cDNA clones
We utilized both PCR and hybridization based strategies to isolate the complete CLTD cDNA. To reduce the effort in direct screening, we prepared 14 pools of 50 000 phage each from a HeLa cell library (Stratagene) and screened phage lysates from each pool with the CLTD-specific primers. Ten of 14 pools were positive. RK1138 was used in combination with vector-specific primer T7 to screen one positive pool, pool 7, which yielded an 834 bp product termed HS1 which was cloned into the Bluescript KS vector (Stratagene) and sequenced. Sequence of this product showed overlap with the V1-5 insert but was distinct from the CLTC cDNA sequence. The HS1 clone was then used as a hybridization probe to isolate 3.7 and 3.2 kb cDNAs (HS6 and HS7) from the HeLa library and a 3.0 kb cDNA (HS2) from a fetal brain cDNA library (Clonetech). All four clones shared sequence overlap ( Fig. 3 ) and could be distinguished from CLTC based on significant differences in the nucleotide sequence. Clones corresponding to CLTC were also isolated from the library screens.
The 5′ RACE (rapid amplification of cDNA ends) technology (36) was used to isolate the portion of the gene containing the translation start site. Nested primers specific to the CLTD cDNA and a primer to a linker that had been ligated to the 5′ terminus of human muscle cDNA were used to recover the 5′ portion of the gene by PCR. Three successive sets of nested primers were required to extend the contig past the predicted translation start site. These efforts yielded overlapping 766, 900 and 273 bp products which were cloned into the PCRII vector (Invitrogen) and corresponded to the 5′ end of the CLTD cDNA (Fig. 3) . The sequence of these clones is distinct from that of CLTC. To confirm the chromosomal origin of the RACE products, PCR primers that span the junction of the second and third RACE products were generated and tested on DNA from 22q11. The primer pair amplified YACs from 22q11 (data not shown). These results show that the CLTD sequence we report here does correspond to the gene on chromosome 22. We also identified RACE products originating from CLTC transcripts.
Sequence analysis
The entire sequence of HS6 and the three RACE products permitted assembly of the complete CLTD cDNA sequence of this gene (GenBank U41763). The assembled sequence consists of 5568 bp and contains an open reading frame of 4914 bp with a good Kozak translation initiation signal (37) . Several stop codons are 5′ to the ATG, suggesting that this is the authentic translation initiation site. An accepted poly(A) signal variant, ATTAAA, is present 17 nucleotides upstream of the poly(A) tail. This alternative poly(A) signal is also seen 16 bp upstream of the poly(A) tail in the rat CHC gene (38) and in both the mouse pancreatic α-amylase (39) and chicken lysozyme genes (40). At the nucleotide sequence level CLTD is 75% homologous to the rat clathrin heavy chain and 74% homologous to both the bovine clathrin heavy chain (GenBank U31757) and human CLTC.
The amino acid sequence of the CLTD product was deduced from the cDNA sequence (Fig. 4) . The protein is composed of 1638 amino acids, has a predicted molecular weight of 186 796 and a pI of 5.55. The other mammalian clathrins are larger, with predicted molecular weights of >191 000. The other mammalian CHCs are 1675 amino acids in length and the yeast protein is also somewhat smaller, having a length of only 1653 amino acids. The CLTD protein is truncated 37 amino acids prior to the C-terminus of the other mammalian clathrin genes. CLTD protein shares 85% identity and 93% similarity to the corresponding N-terminal portion of the mammalian CHCs. The similarity is not confined to any one portion of the protein, but extends throughout the entire molecule. The human CLTC is 99.9% and 99.7% identical to the bovine and rat proteins respectively. CLTD shares an identity of 77% with the Drosophila protein and an identity of 52% within a 1069 amino acid stretch of the C-terminal portion of the yeast protein. The similarity between CLTD and the other CHCs is illustrated in a phylogenetic tree generated from the deduced amino acid sequence of the various CHCs (Fig. 5) . The relationship of the mammalian CHCs suggests that CLTD and the other clathrin heavy chain genes have a common vertebrate ancestor, but that the human CLTD is distinct from all of the other CHCs. This raises the possibility that other mammalian species may also have a homolog to the human CLTD gene.
Functional clathrin molecules form triskelions composed of three heavy and three light chains (30) . Portions of the bovine clathrin heavy chain which are required for binding to the clathrin light chains have recently been determined (41, 42) . The key to the interaction is a predicted coiled-coil between residues 1460 and 1489. Based on an algorithm developed by Lupas et al. (43) a coiled-coil domain is predicted to be present in the same position of CLTD as for the bovine CHC (data not shown).
Expression analysis
The HS1 clone (Fig. 3 ) which corresponds to nucleotides 2331-3065 of the CLTD cDNA and shares an identity of 74% with the corresponding portion of the CLTC gene at the nucleotide sequence level was used as a probe for Northern blot analysis of poly(A) RNA from several human adult tissues. This probe detected an ∼6 kb transcript in skeletal muscle after a 24 h exposure (Fig. 6A) . With a significantly longer exposure (>1 week) less abundant transcripts could be detected in all tissues, with heart showing a slightly greater level of expression than the other tissues (not shown). As a control, the same blot was hybridized with a 3495 bp SmaI-SpeI fragment of the CLTC cDNA which corresponds to the N-terminal region of the protein (Fig. 6B) . This probe detected a message of 6-6.4 kb in all tissues. The complete CLTC cDNA is 6111 bp in length. The CLTC probe also detected a 1.7 kb transcript in skeletal muscle and heart. The 1.7 kb skeletal muscle transcript was not detected using the portions of the CLTD corresponding to the N-terminal half of the protein. The nature of the 1.7 kb transcript is unclear and may represent a CLTC splice variant or it may be the product of an as yet undescribed gene.
Cytogenetic status of CLTD in a VCFS patient
A cosmid containing CLTD, 15A10 (LL22NC03 library), and a cosmid mapping to the telomeric region of chromosome 22 were used for FISH of metaphase chromosomes from a VCFS patient carrying a 22q11 deletion (BM14) and the patient's unaffected mother [BM12; cell lines are described in (28)]. Results from this experiment are shown in Figure 7 . Each member of the pair of chromosome 22 in BM12 showed the two expected distinct signals. In BM14, one chromosome 22 had two signals while the second had only one, that corresponded to the telomeric probe. These results showed that BM14 is hemizygous for CLTD. We have previously shown that BM14 carries a small deletion (28). Therefore we can conclude that all VCFS patients who have detectable deletions are hemizygous for CLTD.
DISCUSSION
We used a hybrid selection protocol to isolate cDNAs encoded within YAC Y5A11 which map to the minimally deleted region in VCFS. One of the cDNA fragments recovered from the YAC encoded a portion of a novel clathrin heavy chain gene that we have designated CLTD. This 301 bp fragment was used to recover the entire coding sequence of the gene. Several lines of evidence support the view that we have recovered a novel expressed CHC gene. The initial cDNA fragment showed homology but not identity, to the previously cloned human CLTC gene. Primers derived from the initial CLTD short fragment cDNA amplified a 119 bp genomic fragment from total human DNA and from somatic cell hybrids containing chromosome 22, but not in hybrids containing chromosome 17 but not chromosome 22. A primer pair derived from the CLTC gene yielded a 290 bp amplification product from human genomic DNA and somatic cell hybrids containing chromosome 17.
The initial CLTD fragment was used to obtain several large cDNA fragments the sequence of which permitted assembly of the complete CLTD coding sequence. The deduced protein is 1638 amino acids in length, 37 amino acids shorter than the other mammalian CHCs. The new gene has 84% identity and 93% similarity to the other vertebrate clathrin heavy chain genes. Human CLTC is more closely related to the other vertebrate CHCs than to CLTD, further suggesting the unique nature of the CLTD gene. The fact that both human clathrin heavy chain genes were isolated from the library screens clearly shows that both genes are expressed. Although clathrin heavy chain genes have been described in many species, this is the first report of a second CHC gene in any species.
Although the cDNAs corresponding to the CLTD were isolated from HeLa and fetal brain cDNA libraries, Northern blot analysis revealed that the level of expression of the CLTD gene is highest in skeletal muscle, with a much lower level of expression in heart and other tissues. Expression of the CLTC gene product is ubiquitous. The observation of CLTD gene expression in muscle is interesting in light of the observations of Kaufman et al. who used a monoclonal antibody made against bovine brain clathrin (44,45) and detected the presence of clathrin in rat skeletal muscle (46) . In addition to the expected signal in coated vesicles and pits, they detected a strong signal along the z-line of the developing sarcomere. The interaction was shown to be specific and that the epitope recognized by the antibody is present in the sarcomere prior to the laying down of titin, myosin heavy chain, actin and desmin. The epitope for X22, the antibody used in these studies, has recently been elucidated (41) and CLTD shares identity in 13 of the 19 amino acids in the epitope, with four additional conservative changes. Based on the immunofluorescence data, it was suggested that clathrin has a novel function in muscle and it was speculated that it may play a mechanochemical role in sarcomere assembly (46) . Given the high similarity of CLTC and CLTD, it is possible that in muscle fibers the X22 antibody recognized CLTD protein. The basis for the differential expression of the two clathrin heavy chain genes and their seemingly distinct biological functions is yet to be determined.
Clathrin is known to form triskelion structures composed of three heavy chains and three light chains (30) . The triskelions form a lattice that line coated vesicles and pits. Adaptor protein (AP) complexes link the clathrin lattice to the plasma membrane and mediate the concentration of specific cell surface receptors required for vesicle-mediated internalization. The AP-2 complex has been shown to bind the cytoplasmic tail of the mannose-6-phosphate receptor, immunoglobulin receptor and the low density lipoprotein (LDL) receptor. Likewise, clathrin-coated vesicles mediate exocytosis from the trans-Golgi network. Mammals have two ubiquitous light chains, LCa and LCb with neuronal-specific splice variants. In neurons, clathrin has been proposed to play additional roles in recycling of presynaptic membranes after synaptic vesicle fusion and neurotransmitter release (30) . Whether the product of the CLTD gene binds LCa and/or LCb or other undiscovered light chains and whether it shares functional properties with CLTC is not known, but the limited levels of CLTD in tissues other than skeletal muscle suggest distinct roles for these proteins.
The CLTD protein shares a 93% similarity to the more ubiquitiously expressed clathrin heavy chain gene. Given the high degree of sequence conservation, it is possible that the muscle CHC may be able to trimerize and interact with many of the proteins with which CHCs are known to associate. The presence of putative coiled-coils further suggests CLTD may interact with clathrin light chains or light chain-like molecules. The significance of the sequence divergence at the C-terminus is unclear. The predicted CLTD gene product is 37 amino acids shorter than the other mammalian CHCs. The C-terminus of the heavy chain was believed to be important for trimerization, but in yeast a CHC truncated at the last 57 amino acids partially rescues CHC-deficient mutants (47) .
Mutations of clathrin have been described in invertebrates. chcyeast are viable in some genetic backgrounds, but growth, morphology, and mating are abnormal (47) (48) (49) (50) . In Dictyostelium, functional inhibition of CHC expression by using antisense oligonucleotides results in organisms that have reduced growth rates in the vegetative state (51) . Four Drosophila chc mutations have been described (52) . Three are lethals with embryos failing to hatch past the first larval stage, and it has been suggested that embryos may rely on maternally derived clathrin up to this point (53) . The fourth allele showed incomplete penetrance and usually resulted in lethality, but surviving flies did develop to maturity and the males were sterile.
VCFS is a complex disorder with significant phenotypic variability and variable penetrance (54) . Because of the large number of phenotypes associated with VCFS and given the large size of the deletions, it is likely that a number of genes in the commonly deleted region contribute to aspects of the phenotype. The approach to understanding the complete etiology of VCFS We have shown that the CLTD gene maps to YACs located between polymorphic markers D22S944 (28) and CA11-22 (manuscript in preparation) both of which are deleted in >80% of VCFS patients. The physical location of the CLTD gene and the direct demonstration of hemizygosity of this locus in one VCFS patient show that all VCFS patients with detectable deletions have at best a single functional copy of CLTD. The expression pattern of CLTD is suggestive of an involvement in one specific VCFS-associated phenotype; hypotonia. In the original study describing VCFS (1), 10 of 12 patients were characterized as having hypotonia at infancy. The study carried out on an additional set of 75 patients (13) , showed that 90% of these patients had pharyngeal hypotonia. However, the biochemical or histopathological basis for the VCFS-associated hypotonia has not been established. The CLTD protein may in fact be serving a key muscle function, and therefore should be considered a candidate for the VCFS-associated hypotonia. Examination of the levels of CLTD expression and sarcomere structure in VCFS patients is necessary to assess the relationship between hemizygosity of this gene and the muscle weakness seen in VCFS patients.
MATERIALS AND METHODS
cDNA selection
The protocol used for cDNA selection was previously described (33, 34) . Briefly, 50 ng of total genomic DNA from the yeast strain containing the Y5A11 YAC was digested with HindIII and spotted onto a Hybond-N membrane (Amersham). The membranes were prehybridized with human and yeast repetitive elements and ribosomal DNA. PCR amplified inserts from the six human cDNA libraries (total fetus from an 8-9 week abortus, fetal brain, adult brain, adult thymus, testes and spleen) were hybridized to the filters. Membranes were washed at 65_C in decreasing concentrations of SSC and SDS. cDNAs retained on the filters were eluted by boiling, re-amplified using linker specific primers and used for a second round of selection. Twice-selected cDNAs were cloned into λgt10 and plated on C600 bacteria.
Hybrid panel PCR
PCR was performed on the somatic cell hybrid panel DNA according to standard procedures (32) . The V1-5 EST primers were RK1138 (5′CCGGGATCCTGAAGAGATTT3′) and RK1139 (5′TGTGCTCGCTGAAGACAGAG3′). Primers designed from the chromosome 17 clathrin heavy chain gene were RK1187 5′AAAACGTGCAGTGGTTCACA3′ and RK1188 5′AGATTCT-GACGGATGTTGGC3′.
Southern blot analysis
Genomic DNAs (10-20 µg/mammalian source, 1-2 µg yeast) were digested with EcoRI overnight. Samples were phenol extracted, precipitated and electrophoresed on 0.8% agarose in 1× TAE (32) . Capillary blotting was used to transfer the DNAs to Hybond-N membranes (Amersham). Probes were prepared by random primed labeling using the Boehringer Mannheim Biochemica kit as per the manufacturer's instructions. Hybridizations were performed at 65_C in Church-Gilbert buffer (0.5 M NaPO 4 pH 7.6, 7% SDS, 1% BSA). Washes were performed at 42_C in 1× SSC, 0.1% SDS for 15 min and at 65_C in 0.5× SSC and 0.1% SDS for 30 min.
Construction of the cDNA contig
The initial HS1 clone was isolated by PCR using primer RK1138 and T7 (5′CGCGTAATACGACTCACTATAGG3′). The PCR product (after 35 cycles with an annealing temperature of 60_C) was cloned into the EcoRV site of Bluescript SKvector (Stratagene).
The HS1 clone was used as a hybridization probe to screen the HeLa (Stratagene) and fetal brain (Clonetech) cDNA libraries. Approximately 500 000 clones were plated on the appropriate bacterial host strain, LE392 (HeLa) or K802 (fetal brain). Phage were grown overnight and plaque lifts performed (32) using HybondN (Amersham). Hybridization conditions were the same as described above. Clones hybridizing to the probe were plaque purified. 5′ Race-ready Human Muscle cDNA was obtained from Clonetech. PCR was performed for 30-35 cycles at an annealing temperatures of 58-62_C using the following three sets of primers: race 1, RK21682 (5′TCCAAGGATGGCATCTGCAAC3′) and RK21683 (5′GGGTGCATGAACAAGGTTCA3′); race 2 RK22325 (5′ATAGCTGCCCTGTGCAAGAG3′) and RK22324 (5′TTCTCACAAACAACTTCTCTGCG3′); race 3 RK23198 (5′GATCTGAAGTGTCTTCCCAGC3′) and RK23197 (5′GTCA-CTCATGTCAATGATCGTG3′). RACE products were cloned into the PCR2 vector (Invitrogen) for sequencing. The primers used to verify the chromosomal origin of the RACE products were RK24442 (5′GCTCACCAACTTTCTCTCGG3′) and RK24443 (5′CTTCCAGCTCCAAAACCTTG3′).
DNA sequencing of cDNA clones
Double-stranded plasmid templates for sequencing were prepared using Qiawell-8 plasmid prep columns (Qiagen) as per the manufacturer's instructions. DNA sequencing was performed on Applied Biosystems Inc. 373/377 DNA sequencers. Sequencing reactions were performed using the dye terminator chemistry and either the ampli-Taq or Taq-fs enzymes (as per the manufacturer's recommendations). Sequence contigs were assembled using the Sequencher program (Genecodes).
Northern blot analysis
Human Multiple Tissue Northern Blot 1 (Clonetech) was purchased. Hybridization and washes were performed in accordance to the manufacturers recommendations.
Fluorescence in situ hybridization
Metaphase spreads were prepared from Epstein-Barr virus-transformed lymphoblast cell lines by colcemid, potassium chloride hypotonic and methanol/acetic acid fixation according to standard protocols. Cosmid DNA was labeled with biotin using the Bio-Nick translation kit (Gibco). The labeled DNA was purified from the reaction using a spin column (Boehringer-Mannheim). A hybridization mixture was made containing 50% formamide, 10% dextran sulfate, 2× SSC, biotinylated probe DNA 10 ng/ml and human Cot1 DNA 100 ng/ml (Gibco-BRL). The mixture was denatured at 75_C for 8 min and preannealed at 37_C for 30 min. The slide was treated at 37_C with RNase A (Sigma) in 2× SSC, washed three times in 2× SSC for 2 min, immediately passed through an alcohol series (70-80-95-100%), and air dried. Chromosomal DNA was denatured at 70_C in 70% formamide, 2× SSC and passed through an alcohol series. Hybridization was performed at 37_C in a moist chamber for 16 h. Washes were carried out at 45_C in 50% formamide, 2× SSC (3 times), 2× SSC once, and 0.1 M PN buffer (0.1 M sodium phosphate/0.1% NP-40, pH 8.0), each for 5 min. Probe was detected using the Fluorescein detection kit (Oncor). Slides were counterstained with propidium iodide (0.6 µg/ml).
